AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases
Seven presentations by AC Immune and its partners at AAT-AD/PD™New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates A […]